About Jubilant DraxImage
Jubilant DraxImage is a Healthcare company based in Quebec City (Canada) founded in 1921. It specializes in diagnostic and therapeutic radiopharmaceuticals. It operates on a B2B model. The company has 3 employees. Its Indian entity Jubilant Draximage Limited reported revenue of ₹1.5 Lakh. Its focus areas include Pharmaceuticals, Radiopharmaceuticals and Diagnostics and Therapeutics. Its competitors include ImaginAb, AC Immune, APRINOIA, Innovate Biopharma and Progenics and 3 more; 7 of its 8 listed competitors have raised funding.
Company details
Jubilant DraxImage, based in Quebec City, focuses on providing healthcare solutions, producing pharmaceutical products, radiopharmaceuticals, and diagnostics and therapeutics. Specializes in diagnostic and therapeutic radiopharmaceuticals. The company prioritizes operational excellence, innovation, and customer-centric approaches for success. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Quebec City, Canada
- Employees 3
- SectorsHealthcare
- Phone•••• ••••
- Website draximage.com
- Social LinkedIn
- Legal Name Jubilant Draximage Limited
- Date of Incorporation 09 Sep, 2009
- Jurisdiction Noida, Uttar Pradesh, India
- Annual Revenue₹1.5 Lakh
FY 2025 · +586% YoY
- Net Loss-₹7 Lakh
FY 2025 · -460% margin
- EBITDA-₹75,000
FY 2025 · -50% margin
- Employee Count3
Associated legal entities of Jubilant DraxImage
Jubilant DraxImage operates through Jubilant Draximage Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Jubilant Draximage Limited CIN U74900UP2009FLC038194 | Active | 09 Sep 2009 | Noida, Uttar Pradesh | ₹0.0 Cr | 3 | 3 | View details |
Board of directors of Jubilant Draximage Limited (Jubilant DraxImage)
Jubilant Draximage Limited is the primary company behind Jubilant DraxImage. The board of Jubilant Draximage Limited currently have 3 directors; the longest-serving is Arun Kumar Sharma, appointed in 2020. 19 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Arun Kumar Sharma DIN 06991435 | Director | 07 Jul 2020 | 6 yrs 3 mo | Jubilant Draximage Limited |
| Devarajan Jagannathan DIN 09244642 | Director | 27 Sep 2024 | 2 yrs | Jubilant Draximage Limited |
| Sanjay Gupta DIN 00095510 | Director | 25 Nov 2024 | 1 yr 10 mo | Jubilant Draximage Limited |
Financials of Jubilant DraxImage
Figures of Jubilant Draximage Limited, the primary company behind Jubilant DraxImage, for FY 2025. Revenue was ₹1.5 Lakh (+586% year on year). Net loss was -₹7 Lakh (-460% margin). EBITDA was -₹75,000 (-50% margin). Revenue has grown at a compounded annual rate of +126% over three years and -40% over five years.
- ₹1.5 LakhRevenue · FY 2025 · +586% YoY
- -₹7 LakhNet loss · -460% margin
- -₹75,000EBITDA · -50% margin
- ₹7.8 LakhPaid-up capital
- 3Employees (provident fund records)
- +126%Revenue CAGR, 3 years
- -40%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Jubilant Draximage Limited are on its company page.
Detailed financial statements for Jubilant DraxImage
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Jubilant DraxImage
Jubilant DraxImage has 8 listed competitors in our database, 7 of them funded. They include ImaginAb, AC Immune, APRINOIA, Innovate Biopharma and Progenics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| imaginab.com | 2007 | Los Angeles, United States | $59.64M | 17 | ImaginAb is focused on developing advanced immuno-oncology imaging technologies. | |
| acimmune.com | 2003 | Lausanne, Switzerland | $119.82M | – | Antibodies, small molecules, and vaccines are developed for neurodegenerative diseases. | |
| aprinoia.com | 2015 | Taipei, Taiwan | $51.1M | 15 | Diagnostics and therapeutics for neurodegenerative disorders are developed. | |
| innovatebiopharma.com | 2012 | Raleigh, United States | $48.58M | – | Small molecule drugs and imaging agent for GI disorders | |
| progenics.com | 1988 | United States | – | 53 | Imaging compounds & targeted radiotherapies to detect and treat prostate cancer. | |
| blueearthdiagnostics.com | 2014 | Oxford, United Kingdom | $49.42M | 38 | Radioactive molecular imaging agents for cancer are developed. | |
| nuviewlifesciences.com | 2005 | Park, United States | $90M | – | Cancer diagnosis devices targeting VPAC1 receptors are developed. | |
| bestabt.com | 2006 | Louisville, United States | $29.07M | – | Biomarker generators for PET molecular imaging are manufactured. |
Detailed competitors of Jubilant DraxImage
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Jubilant DraxImage
Websites that share an audience with Jubilant DraxImage (draximage.com).
Websites whose visitors overlap most with Jubilant DraxImage. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| arqule.com | 100% | – | – | View details | |
| jubilantbiosys.com | 99% | 12.2K | #2,731,637 | View details | |
| jublhs.com | 97% | 11.4K | #2,238,667 | View details | |
| onyx-pharm.com | 81% | – | – | View details |
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Jubilant DraxImage (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Jubilant Draximage
Complete news archive for Jubilant DraxImage
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jubilant DraxImage
Jubilant DraxImage was founded in 1921.
Jubilant DraxImage is headquartered in Quebec City, Canada. It is registered at Quebec City, Quebec, Canada.
Jubilant DraxImage has 3 employees.
The primary company behind Jubilant DraxImage, Jubilant Draximage Limited, reported revenue of ₹1.5 Lakh for FY 2025, up 586% year on year.
Jubilant DraxImage, based in Quebec City, focuses on providing healthcare solutions, producing pharmaceutical products, radiopharmaceuticals, and diagnostics and therapeutics. Specializes in diagnostic and therapeutic radiopharmaceuticals. The company prioritizes operational excellence, innovation, and customer-centric approaches for success. It continues to evolve, meeting industry challenges with strategic approaches.
Jubilant DraxImage operates through Jubilant Draximage Limited.
The legal entities of Jubilant DraxImage currently have 3 directors, including Sanjay Gupta, Arun Kumar Sharma, Devarajan Jagannathan.